News Image

Why NASDAQ:NBIX Is a Standout High-Growth Stock in a Consolidation Phase.

By Mill Chart

Last update: Apr 11, 2024

In this article, we'll take a closer look at NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX) as a potential candidate for growth investing. While it's important for investors to conduct their own research, NEUROCRINE BIOSCIENCES INC has piqued our interest by appearing on our strong growth and breakout radar. Let's explore further.

How do we evaluate the Growth for NASDAQ:NBIX?

A key component of ChartMill's stock assessment is the Growth Rating, which spans from 0 to 10. This rating evaluates diverse growth factors, such as EPS and revenue growth, considering both past performance and future projections. NASDAQ:NBIX has received a 9 out of 10:

  • NBIX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 58.17%, which is quite impressive.
  • The Earnings Per Share has been growing by 70.09% on average over the past years. This is a very strong growth
  • Looking at the last year, NBIX shows a very strong growth in Revenue. The Revenue has grown by 26.76%.
  • Measured over the past years, NBIX shows a very strong growth in Revenue. The Revenue has been growing by 33.13% on average per year.
  • Based on estimates for the next years, NBIX will show a very strong growth in Earnings Per Share. The EPS will grow by 42.64% on average per year.
  • NBIX is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 13.87% yearly.

How We Gauge Health for NASDAQ:NBIX

ChartMill assigns a proprietary Health Rating to each stock. The score is computed by evaluating various liquidity and solvency ratios and ranges from 0 to 10. NASDAQ:NBIX was assigned a score of 7 for health:

  • NBIX has an Altman-Z score of 9.35. This indicates that NBIX is financially healthy and has little risk of bankruptcy at the moment.
  • NBIX's Altman-Z score of 9.35 is amongst the best of the industry. NBIX outperforms 85.30% of its industry peers.
  • There is no outstanding debt for NBIX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
  • NBIX has a Current Ratio of 2.45. This indicates that NBIX is financially healthy and has no problem in meeting its short term obligations.
  • NBIX has a Quick Ratio of 2.40. This indicates that NBIX is financially healthy and has no problem in meeting its short term obligations.

Profitability Insights: NASDAQ:NBIX

Discover ChartMill's exclusive Profitability Rating, a proprietary metric that assesses stocks on a scale of 0 to 10. It takes into consideration various profitability ratios and margins, both in absolute terms and relative to industry peers. Notably, NASDAQ:NBIX has achieved a 9:

  • With an excellent Return On Assets value of 7.68%, NBIX belongs to the best of the industry, outperforming 96.75% of the companies in the same industry.
  • Looking at the Return On Equity, with a value of 11.19%, NBIX belongs to the top of the industry, outperforming 96.41% of the companies in the same industry.
  • Looking at the Return On Invested Capital, with a value of 11.21%, NBIX belongs to the top of the industry, outperforming 96.92% of the companies in the same industry.
  • The last Return On Invested Capital (11.21%) for NBIX is above the 3 year average (9.89%), which is a sign of increasing profitability.
  • With an excellent Profit Margin value of 13.23%, NBIX belongs to the best of the industry, outperforming 96.92% of the companies in the same industry.
  • NBIX's Profit Margin has improved in the last couple of years.
  • NBIX's Operating Margin of 20.92% is amongst the best of the industry. NBIX outperforms 97.09% of its industry peers.
  • NBIX's Operating Margin has improved in the last couple of years.
  • With an excellent Gross Margin value of 97.90%, NBIX belongs to the best of the industry, outperforming 98.12% of the companies in the same industry.

How does the Setup look for NASDAQ:NBIX

ChartMill also assign a Setup Rating to every stock. With this score it is determined to what extend the stock has been trading in a range in the recent days and weeks. This score also ranges from 0 to 10 and is updated daily. The setup score evaluates various short term technical indicators. NASDAQ:NBIX scores a 8 out of 10:

Besides having an excellent technical rating, NBIX also presents a decent setup pattern. We see reduced volatility while prices have been consolidating in the most recent period. There is a resistance zone just above the current price starting at 138.55. Right above this resistance zone may be a good entry point. There is a support zone below the current price at 131.29, a Stop Loss order could be placed below this zone.

Our Strong Growth screener lists more Strong Growth stocks and is updated daily.

For an up to date full fundamental analysis you can check the fundamental report of NBIX

Our latest full technical report of NBIX contains the most current technical analsysis.

Keep in mind

This is not investing advice! The article highlights some of the observations at the time of writing, but you should always make your own analysis and invest based on your own insights.

Back

NEUROCRINE BIOSCIENCES INC

NASDAQ:NBIX (5/29/2024, 7:19:44 PM)

Premarket: 134.6 -0.02 (-0.01%)

134.62

-5.86 (-4.17%)

NBIX News

News Image17 hours ago - Neurocrine Biosciences, Inc.Neurocrine Biosciences to Participate at Investor Conferences in June

/PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will participate at two upcoming investor conferences in June. Kevin Gorman, Chief Executive...

News Image2 days ago - Neurocrine Biosciences, Inc.Neurocrine Biosciences Announces CEO Succession Plan

/PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX), today announced that Kevin Gorman, Ph.D., will retire as Chief Executive Officer of Neurocrine on...

News Image2 days ago - Neurocrine Biosciences, Inc.Neurocrine Biosciences to Present New Phase 3 CAHtalyst™ Data in Adult and Pediatric Patients with CAH and Study Data for Modified-Release Hydrocortisone in Primary Adrenal Insufficiency and CAH at ENDO 2024

/PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that it will present key information from its neuroendocrinology pipeline,...

News Image3 days ago - ChartmillExploring NASDAQ:NBIX's quality characteristics.

Reasonable growth and debt and a high ROIC for NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX).

News Image6 days ago - ChartmillExploring the Growth Potential of NASDAQ:NBIX as It Nears a Breakout.

NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX) qualifies as a high growth stock and is consolidating.

News Image7 days ago - ChartmillIn the world of growth stocks, NASDAQ:NBIX shines as a value proposition.

Looking for growth without the hefty price tag? Consider NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX).

News Image9 days ago - Neurocrine Biosciences, Inc.Neurocrine Biosciences Announces Publication of Phase 3 KINECT®-4 Post Hoc Analysis Demonstrating Clinically Meaningful and Sustained Improvement in Tardive Dyskinesia With Long-Term Use of INGREZZA® (valbenazine) Capsules

/PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the publication of data from a post hoc analysis of the Phase 3 KINECT®-4 study of...

News Image13 days ago - Market News VideoInteresting NBIX Put And Call Options For July 19th
News Image14 days ago - Market News VideoNeurocrine Biosciences Moves Up In Market Cap Rank, Passing Pool
News Image16 days ago - Neurocrine Biosciences, Inc.Neurocrine Biosciences Presented Baseline Data from the CAHtalyst™ Program in CAH and Study Data for Modified-Release Hydrocortisone in Primary Adrenal Insufficiency and CAH at ECE 2024

- CAHtalyst™ Phase 3 Baseline Characteristics Highlight Limitations of Current CAH Treatment Paradigm in Children, Adolescents and Adults - Phase 2 Study for...

News Image21 days ago - Neurocrine Biosciences, Inc.Neurocrine Biosciences Presents CAHtalyst™ Adult Study Baseline Characteristics and Data on Impact of Supraphysiologic Glucocorticoid Therapy at AACE 2024

/PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that it will present CAHtalyst™ Adult Phase 3 clinical study baseline...

News Image21 days ago - Neurocrine Biosciences, Inc.Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating Effects of NBI-1076986 in Healthy Adults

/PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the initiation of its Phase 1 first-in-human clinical study to evaluate the safety,...

NBIX Links
Follow us for more